What are the differences between Gilbert syndrome, Crigler‑Najjar syndrome, and Rotor syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differentiating Gilbert, Crigler-Najjar, and Rotor Syndromes

Overview of Key Distinctions

These three hereditary hyperbilirubinemia syndromes differ fundamentally in their type of bilirubin elevation, severity, enzyme deficiency, and clinical outcomes. Gilbert and Crigler-Najjar syndromes cause unconjugated hyperbilirubinemia due to impaired glucuronidation, while Rotor syndrome causes conjugated hyperbilirubinemia due to impaired hepatic storage 1, 2, 3.


Gilbert Syndrome

Pathophysiology and Epidemiology

  • Affects 5-10% of the general population, making it the most common hereditary hyperbilirubinemia 1, 4.
  • Caused by reduced UGT1A1 enzyme activity to 20-30% of normal, resulting in impaired bilirubin conjugation with glucuronic acid 1.

Laboratory Characteristics

  • Unconjugated (indirect) bilirubin comprises >70-80% of total bilirubin 4.
  • Total bilirubin rarely exceeds 4-5 mg/dL (68-85 μmol/L) 1, 4.
  • All liver enzymes (ALT, AST, alkaline phosphatase) remain completely normal 4.
  • Conjugated bilirubin must be <20-30% of total bilirubin 1, 4.
  • No evidence of hemolysis (normal reticulocyte count, haptoglobin, CBC) 4.

Clinical Features

  • Entirely benign condition requiring only reassurance 4.
  • Intermittent jaundice triggered by fasting, stress, or illness 1.
  • Normal life expectancy with no treatment needed 4.
  • May increase risk of drug-associated toxicity due to impaired glucuronidation 2.

Diagnostic Confirmation

  • DNA testing for UGT1A1 gene mutations provides definitive diagnosis when clinical picture is unclear 4.

Crigler-Najjar Syndrome

Type I (Severe Form)

  • Presents in neonates with severe unconjugated hyperbilirubinemia requiring immediate phototherapy and often liver transplantation to prevent kernicterus 4.
  • Complete absence of UGT1A1 enzyme activity 3, 5, 6.
  • Bilirubin levels typically exceed 20 mg/dL without treatment 5.
  • Fatal without aggressive intervention 3, 6.
  • Does not respond to phenobarbital therapy 6.

Type II (Moderate Form)

  • Partial UGT1A1 enzyme deficiency with residual activity 6.
  • Bilirubin levels typically 6-20 mg/dL 6.
  • Responds to phenobarbital, which induces enzyme activity 6.
  • Lower risk of kernicterus compared to Type I 6.

Relationship to Gilbert Syndrome

  • Crigler-Najjar and Gilbert syndromes represent a spectrum of the same genetic defect affecting UGT1A1, with severity determined by the degree of enzyme deficiency 2, 7, 6.
  • Combined genetic defects (e.g., Crigler-Najjar Type I with Gilbert-type mutations) cause more severe clinical disease 5.
  • Both conditions show increased proportion of bilirubin monoglucuronide in bile when enzyme deficiency is present 7.

Rotor Syndrome

Pathophysiology

  • Fundamentally different mechanism: impaired hepatic storage capacity rather than conjugation defect 7.
  • Results in conjugated (direct) hyperbilirubinemia 2, 3.
  • Autosomal recessive inheritance pattern 3.

Laboratory Characteristics

  • Mixed direct and indirect hyperbilirubinemia with elevated conjugated fraction 2.
  • Liver enzymes may be normal or mildly elevated 2.
  • Distinctive urinary coproporphyrin excretion pattern that differentiates it from Dubin-Johnson syndrome 2, 7.
  • Total urinary coproporphyrin excretion is markedly increased (2.5-5 times normal) 7.

Clinical Features

  • Rare condition with benign course 3.
  • No treatment required 3.
  • Normal life expectancy 3.

Key Distinction from Dubin-Johnson Syndrome

  • Rotor syndrome involves impaired hepatic storage, while Dubin-Johnson involves impaired excretion 7.
  • The distinct urinary coproporphyrin patterns provide clear differentiation between these two conjugated hyperbilirubinemia syndromes 7.

Diagnostic Algorithm

Step 1: Fractionate Bilirubin

  • Measure total and direct bilirubin to determine if hyperbilirubinemia is conjugated or unconjugated 1, 4.
  • Direct bilirubin >35% of total indicates conjugated hyperbilirubinemia 1, 8.

Step 2: If Unconjugated (Indirect >70%)

  • Check complete liver panel (ALT, AST, alkaline phosphatase) 4.
  • If all liver enzymes are normal and unconjugated bilirubin <5 mg/dL: likely Gilbert syndrome 4.
  • If severe elevation (>20 mg/dL) in neonate: Crigler-Najjar Type I 4, 5.
  • Rule out hemolysis with reticulocyte count, haptoglobin, and CBC 4.
  • Consider UGT1A1 genetic testing for confirmation 4.

Step 3: If Conjugated (Direct >35%)

  • Perform abdominal ultrasound to exclude biliary obstruction 1, 8.
  • If ultrasound normal and mixed hyperbilirubinemia present: consider Rotor syndrome 2, 7.
  • Measure urinary coproporphyrin excretion pattern to differentiate Rotor from Dubin-Johnson 7.

Critical Clinical Pitfalls

  • Never assume isolated hyperbilirubinemia is benign without proper fractionation and liver enzyme assessment 8, 4.
  • Conjugated bilirubin >30% of total excludes Gilbert syndrome and mandates evaluation for hepatobiliary pathology 4.
  • Any elevation in ALT, AST, or alkaline phosphatase excludes Gilbert syndrome 4.
  • Direct bilirubin includes both conjugated bilirubin AND delta bilirubin (albumin-bound with 21-day half-life), which can cause prolonged hyperbilirubinemia even after resolution of underlying cause 1, 8, 4.
  • Combined genetic defects can cause more severe phenotypes than expected from single mutations 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hereditary hyperbilirubinemias.

Srpski arhiv za celokupno lekarstvo, 2014

Guideline

Laboratory Diagnosis of Gilbert's Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Bilirubin in Urine: Clinical Significance and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.